Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $0.79 and last traded at $0.77, with a volume of 4164216 shares changing hands. The stock had previously closed at $0.74.
Elite Pharmaceuticals Price Performance
The stock has a market cap of $827.87 million, a P/E ratio of -38.75 and a beta of 0.17. The company's fifty day simple moving average is $0.49 and its 200-day simple moving average is $0.50. The company has a current ratio of 3.27, a quick ratio of 1.90 and a debt-to-equity ratio of 0.12.
Elite Pharmaceuticals Company Profile
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
